Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H26N4O2 |
Molecular Weight | 354.446 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)C1=CC=C(OCCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
InChI
InChIKey=OQLKNTOKMBVBKV-UHFFFAOYSA-N
InChI=1S/C20H26N4O2/c21-19(22)15-5-9-17(10-6-15)25-13-3-1-2-4-14-26-18-11-7-16(8-12-18)20(23)24/h5-12H,1-4,13-14H2,(H3,21,22)(H3,23,24)
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia. | 1990 Apr |
|
Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. | 1990 Jul |
|
1,5-Bis(4-amidinophenoxy)pentane (pentamidine) is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 binding sites. | 1998 Jul 17 |
|
[Treatment of Acanthamoeba keratitis: possibilities, problems, and new approaches]. | 2003 |
|
Bilateral Acanthamoeba keratitis with late recurrence of the infection in a corneal graft: a case report. | 2003 Apr |
|
Opportunistic amoebae: challenges in prophylaxis and treatment. | 2004 Feb |
|
[Contact allergy to antiseptics: 75 cases analyzed by the dermato-allergovigilance network (Revidal)]. | 2005 Dec |
|
Acanthamoeba keratitis during orthokeratology. | 2005 Oct |
|
Acanthamoeba keratitis in a 5-year-old boy without a history of contact lens usage. | 2006 Apr |
|
Systemic allergy to topical hexamidine. | 2006 Aug 7 |
|
A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents. | 2006 Jun |
|
[Clinical tolerance of cutaneous antiseptics in 3,403 patients in France]. | 2006 Oct |
|
[Towards new antibacterial drugs. Interest of para-guanidinoethylcalix[4]arene]. | 2006 Oct-Nov |
|
Final report on the safety assessment of Hexamidine and Hexamidine Diisethionate. | 2007 |
|
[Acanthamoeba keratitis: about the first two Tunisian cases]. | 2007 Feb |
|
Visual outcome and rehabilitation in a case of bilateral acanthamoeba sclerokeratitis. | 2007 Oct |
|
In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria. | 2007 Sep |
|
Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. | 2007 Sep |
|
Bilateral acanthamoeba keratitis. | 2008 Feb |
|
Understanding metabolic pathways for skin anti-aging. | 2009 Jul |
|
Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. | 2009 May |
|
Painless Acanthamoeba keratitis in a soft contact lens wearer--case report. | 2009 Sep |
|
[Infectious keratitis and cosmetic lenses: a five-case retrospective study]. | 2010 Apr |
|
[Effect of psychotropic drugs on activity of anticonvulsants in maximal electroshock test]. | 2010 Aug |
|
Action potential-enhanced ATP release from taste cells through hemichannels. | 2010 Aug |
|
Antiseptic properties of two calix[4]arenes derivatives on the human coronavirus 229E. | 2010 Dec |
|
[Acanthamoeba keratitis. Report of 3 cases diagnosed in central Tunisia]. | 2010 Feb |
|
Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis. | 2010 Jan |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R02AA18
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
||
|
WHO-VATC |
QD08AC04
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
||
|
NCI_THESAURUS |
C258
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
||
|
WHO-VATC |
QS01AX08
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
||
|
WHO-VATC |
QR01AX07
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
||
|
WHO-ATC |
D08AC04
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
||
|
WHO-VATC |
QR02AA18
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
||
|
WHO-VATC |
QS03AA05
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
||
|
WHO-ATC |
S01AX08
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
||
|
WHO-VATC |
QD08AC54
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
||
|
WHO-ATC |
S03AA05
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
||
|
WHO-ATC |
R01AX07
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3483C2H13H
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
87184
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
3811-75-4
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
C018961
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
HEXAMIDINE
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
m6000
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB03808
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
1393
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
3275
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
SUB08029MIG
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
CHEMBL25105
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
DTXSID60191524
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
100000083975
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
26849
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | RxNorm | ||
|
65130
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY | |||
|
C65849
Created by
admin on Fri Dec 15 16:37:07 UTC 2023 , Edited by admin on Fri Dec 15 16:37:07 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)